Beam Therapeutics Inc. Derivative Liability, Noncurrent
Beam Therapeutics Inc. (BEAM) had Derivative Liability, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-02-24
- 2025-12-31: Derivative Liability, Noncurrent $0.00.
- 2025-09-30: Derivative Liability, Noncurrent $6.65M.
- 2025-06-30: Derivative Liability, Noncurrent $6.50M.
- 2025-03-31: Derivative Liability, Noncurrent $6.34M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $6.65M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $6.50M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $6.34M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $5.40M 10-K · filed 2026-02-24 |
| 2024-09-30 | $5.28M 10-Q · filed 2024-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |